Cargando…
Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection
The impact of the coronavirus disease 2019 (COVID‐19) pandemic among patients with chronic liver disease is unknown. Given the high prevalence of nonalcoholic fatty liver disease (NAFLD), we determined the predictors of mortality and hospital resource use among patients with NAFLD admitted with COVI...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426701/ https://www.ncbi.nlm.nih.gov/pubmed/34558853 http://dx.doi.org/10.1002/hep4.1802 |
_version_ | 1783750094487552000 |
---|---|
author | Younossi, Zobair M. Stepanova, Maria Lam, Brian Cable, Rebecca Felix, Sean Jeffers, Thomas Younossi, Elena Pham, Huong Srishord, Manirath Austin, Patrick Estep, Michael Terra, Kathy Escheik, Carey de Avila, Leyla Golabi, Pegah Kolacevski, Andrej Racila, Andrei Henry, Linda Gerber, Lynn |
author_facet | Younossi, Zobair M. Stepanova, Maria Lam, Brian Cable, Rebecca Felix, Sean Jeffers, Thomas Younossi, Elena Pham, Huong Srishord, Manirath Austin, Patrick Estep, Michael Terra, Kathy Escheik, Carey de Avila, Leyla Golabi, Pegah Kolacevski, Andrej Racila, Andrei Henry, Linda Gerber, Lynn |
author_sort | Younossi, Zobair M. |
collection | PubMed |
description | The impact of the coronavirus disease 2019 (COVID‐19) pandemic among patients with chronic liver disease is unknown. Given the high prevalence of nonalcoholic fatty liver disease (NAFLD), we determined the predictors of mortality and hospital resource use among patients with NAFLD admitted with COVID‐19 by using electronic medical records data for adult patients with COVID‐19 hospitalized in a multihospital health system who were discharged between March and December 2020. NAFLD was diagnosed by imaging or liver biopsy without other liver diseases. Charlson’s comorbidity index (CCI) and Elixhauser comorbidity index (ECI) scores were calculated. In the study sample, among the 4,835 patients hospitalized for COVID‐19, 553 had NAFLD (age: 55 ± 16 years, 51% male, 17% White, 11% Black, 58% Hispanic, 8% Asian, 5% from congregated living, 58% obese, 15% morbid obesity [body mass index ≥ 40], 51% type 2 diabetes, 63% hypertension, mean [SD] baseline CCI of 3.9 [3.2], and baseline ECI of 13.4 [11.3]). On admission, patients with NAFLD had more respiratory symptoms, higher body temperature and heart rate, higher alanine aminotransferase and aspartate aminotransferase than non‐NAFLD controls (n = 2,736; P < 0.05). Of the patients with NAFLD infected with COVID‐19, 3.9% experienced acute liver injury. The NAFLD group had significantly longer length of stay, intensive care unit use, and mechanical ventilation, with a crude inpatient mortality rate of 11%. In multivariate analysis, independent predictors of inpatient mortality among patients with NAFLD infected with COVID‐19 were older age, morbid obesity, ECI score ≥ 11, higher Fibrosis‐4 Index (FIB‐4) score, and oxygen saturation <90% (all P < 0.05), but not sex, race/ethnicity, or any individual comorbidity (all P > 0.05). Conclusion: Patients with NAFLD infected with COVID‐19 tend to be sicker on admission and require more hospital resource use. Independent predictors of mortality included higher FIB‐4 and multimorbidity scores, morbid obesity, older age, and hypoxemia on admission. |
format | Online Article Text |
id | pubmed-8426701 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84267012021-09-09 Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection Younossi, Zobair M. Stepanova, Maria Lam, Brian Cable, Rebecca Felix, Sean Jeffers, Thomas Younossi, Elena Pham, Huong Srishord, Manirath Austin, Patrick Estep, Michael Terra, Kathy Escheik, Carey de Avila, Leyla Golabi, Pegah Kolacevski, Andrej Racila, Andrei Henry, Linda Gerber, Lynn Hepatol Commun Original Articles The impact of the coronavirus disease 2019 (COVID‐19) pandemic among patients with chronic liver disease is unknown. Given the high prevalence of nonalcoholic fatty liver disease (NAFLD), we determined the predictors of mortality and hospital resource use among patients with NAFLD admitted with COVID‐19 by using electronic medical records data for adult patients with COVID‐19 hospitalized in a multihospital health system who were discharged between March and December 2020. NAFLD was diagnosed by imaging or liver biopsy without other liver diseases. Charlson’s comorbidity index (CCI) and Elixhauser comorbidity index (ECI) scores were calculated. In the study sample, among the 4,835 patients hospitalized for COVID‐19, 553 had NAFLD (age: 55 ± 16 years, 51% male, 17% White, 11% Black, 58% Hispanic, 8% Asian, 5% from congregated living, 58% obese, 15% morbid obesity [body mass index ≥ 40], 51% type 2 diabetes, 63% hypertension, mean [SD] baseline CCI of 3.9 [3.2], and baseline ECI of 13.4 [11.3]). On admission, patients with NAFLD had more respiratory symptoms, higher body temperature and heart rate, higher alanine aminotransferase and aspartate aminotransferase than non‐NAFLD controls (n = 2,736; P < 0.05). Of the patients with NAFLD infected with COVID‐19, 3.9% experienced acute liver injury. The NAFLD group had significantly longer length of stay, intensive care unit use, and mechanical ventilation, with a crude inpatient mortality rate of 11%. In multivariate analysis, independent predictors of inpatient mortality among patients with NAFLD infected with COVID‐19 were older age, morbid obesity, ECI score ≥ 11, higher Fibrosis‐4 Index (FIB‐4) score, and oxygen saturation <90% (all P < 0.05), but not sex, race/ethnicity, or any individual comorbidity (all P > 0.05). Conclusion: Patients with NAFLD infected with COVID‐19 tend to be sicker on admission and require more hospital resource use. Independent predictors of mortality included higher FIB‐4 and multimorbidity scores, morbid obesity, older age, and hypoxemia on admission. John Wiley and Sons Inc. 2021-08-24 /pmc/articles/PMC8426701/ /pubmed/34558853 http://dx.doi.org/10.1002/hep4.1802 Text en © 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Younossi, Zobair M. Stepanova, Maria Lam, Brian Cable, Rebecca Felix, Sean Jeffers, Thomas Younossi, Elena Pham, Huong Srishord, Manirath Austin, Patrick Estep, Michael Terra, Kathy Escheik, Carey de Avila, Leyla Golabi, Pegah Kolacevski, Andrej Racila, Andrei Henry, Linda Gerber, Lynn Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection |
title | Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection |
title_full | Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection |
title_fullStr | Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection |
title_full_unstemmed | Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection |
title_short | Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection |
title_sort | independent predictors of mortality among patients with nafld hospitalized with covid‐19 infection |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426701/ https://www.ncbi.nlm.nih.gov/pubmed/34558853 http://dx.doi.org/10.1002/hep4.1802 |
work_keys_str_mv | AT younossizobairm independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection AT stepanovamaria independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection AT lambrian independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection AT cablerebecca independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection AT felixsean independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection AT jeffersthomas independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection AT younossielena independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection AT phamhuong independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection AT srishordmanirath independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection AT austinpatrick independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection AT estepmichael independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection AT terrakathy independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection AT escheikcarey independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection AT deavilaleyla independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection AT golabipegah independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection AT kolacevskiandrej independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection AT racilaandrei independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection AT henrylinda independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection AT gerberlynn independentpredictorsofmortalityamongpatientswithnafldhospitalizedwithcovid19infection |